<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82377">
  <stage>Registered</stage>
  <submitdate>29/10/2007</submitdate>
  <approvaldate>9/11/2007</approvaldate>
  <actrnumber>ACTRN12607000581460</actrnumber>
  <trial_identification>
    <studytitle>A single-centre, randomised, double-blind, vehicle-controlled, proof-of-concept study of glycopyrrolate in the treatment of primary axillary hyperhidrosis</studytitle>
    <scientifictitle>A single-centre, randomised, double-blind, vehicle-controlled, proof-of-concept study of glycopyrrolate in the treatment of primary axillary hyperhidrosis</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Axillary Hyperhidrosis</healthcondition>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Dermatological conditions</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>2% or 4% glycopyrrolate applied once daily to each armpit for 4 weeks</interventions>
    <comparator>Ethanol solution applied once daily to each armpit for 4 weeks</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Gravimetric asessment of sweating</outcome>
      <timepoint>Baseline then 1, 2, 3, 4 and 6 weeks after commencement of intervention</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Hyperhidrosis disease severity scale</outcome>
      <timepoint>Baseline then 1, 2, 3, 4 and 6 weks after commencemnt of intervention</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Saftey of intervention by recording vital signs and adverse events</outcome>
      <timepoint>Baseline then 1, 2, 3, 4 and 6 weks after commencemnt of intervention</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Bioavailability of glycopyrrolate</outcome>
      <timepoint>Baseline then 1, 2, 3, 4 and 6 weks after commencemnt of intervention</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1.  16 years of age or older
2.  Diagnosis of primary, axilliary hyperhidrosis of at least 6 months duration
3.  Ability and willingness to follow all study procedurs, attend all scheduled visits, and successfully complete the study
4.  Sign a written informed consent form</inclusivecriteria>
    <inclusiveminage>16</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1.  Intravenous (IV) or oral glycopyrrolate treatment within 8 weeks prior to study enrollment.
2.  Prior axillary use of non prescription/ over-the-counter (OTC antiperspirants containing aluminum chloride (or other metallic salts) within 24 hours of study enrollment.
3.  Prior axillary use of prescription antiperspirants containing aluminum chloride (or other metallic salts) within the 4 weeks.
4.  Known history of a condition  that may cause secondary hyperhidrosis.
5.  Known history of a condition that could be exacerbated by the use of anticholinergics. 
6.  Active infection of the axillae. 
7.  Prior treatment with botulinum toxin (eg, BotoxÂ®) for axillary hyperhidrosis within 1 year.
8.  Prior treatment with iontophoresis within 4 weeks. 
9.  Prior surgical procedure for hyperhidrosis. 
10.  Treatment with psychotherapeutic agents within the 8 weeks.
11.  Treatment with topical or systemic anticholinergics, adrenergic agonists (clonidine), or beta-blockers within 8 weeks.
12.  Abnormal blood pressure.
13.  Pregnant women, women who are breast feeding, or sexually active women of child bearing potential who are not practicing an acceptable method of birth control.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>19/10/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>36</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Stiefel Laboratories</primarysponsorname>
    <primarysponsoraddress>3160 Porter Drive
Palo Alto, CA, 94304</primarysponsoraddress>
    <primarysponsorcountry>United States of America</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Stiefel Laboratories</fundingname>
      <fundingaddress>3160 Porter Drive
Palo Alto, CA, 94304</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Novotech (Austalia) Pty Ltd</sponsorname>
      <sponsoraddress>Level 3, 19 Harris St
Pyrmont, NSW, 2009</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of the study is to test if an experimental topical drug is effective in reducing under-arm perspiration in people who have excessive under-arm perspiration</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Bellberry Human Research Ethics Committee</ethicname>
      <ethicaddress>1st Floor, 71 Anzac Hwy
Ashford, SA, 5035</ethicaddress>
      <ethicapprovaldate>21/09/2007</ethicapprovaldate>
      <hrec>B91/07</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Sabra Abraham</name>
      <address>3160 Porter Drive
Palo Alto, CA, 94304</address>
      <phone>+1 650 843 2831</phone>
      <fax />
      <email>sabra.abraham@stiefel.com</email>
      <country>United States of America</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Lysandra Tassone</name>
      <address>Novotech (Australia) Pty Ltd
Level 1, Suite 35
49 University St
Carlton, Vic, 3053</address>
      <phone>+61 3 9341 1900</phone>
      <fax>+61 3 9347 6288</fax>
      <email>lysandra.tassone@novotech-cro.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>